glp 1 application Mechanism of action of GLP-1 agonists GLP-1 Receptor Agonists as Treatments

Zar, ND, PharmD designs our clinical protocols

Lee SH, Takahashi K, Hatakawa Y, Oe T

Over time, pharmacological engineering enabled: Short-acting injectables (e.g., exenatide) Long-acting once-weekly injectables (liraglutide, semaglutide) Multi-target incretin therapies (tirzepatide) Oral peptide formulations and now oral small molecules The most recent breakthrough is the development of orally available GLP-1 receptor agonists, including: Orforglipron (Lilly) Elecoglipron (AstraZeneca) These compounds eliminate the need for injection and could dramatically expand accessibility and adherence in obesity and diabetes populations

Form: oil-based injectable, 250mg/ml, 10ml per vial

That includes a complete allergy history